We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-2.73%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$535M
AUM Growth
-$66.7M
Cap. Flow
+$12.3M
Cap. Flow %
2.29%
Top 10 Hldgs %
59.08%
Holding
57
New
9
Increased
13
Reduced
14
Closed
9

Top Buys

Rank Stock Value
1
SMLR
Semler Scientific
SMLR
+$28.5M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$4.22M
3
KROS icon
Keros Therapeutics
KROS
+$4.18M
4
FOLD
Amicus Therapeutics
FOLD
+$3.28M
5
CMRX
Chimerix, Inc.
CMRX
+$2.75M

Top Sells

Rank Stock Value
1
EPIX
ESSA Pharma
EPIX
+$8.12M
2
MCRB icon
Seres Therapeutics
MCRB
+$5.96M
3
WGS icon
GeneDx Holdings
WGS
+$5.24M
4
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$3.82M
5
KZR
Kezar Life Sciences
KZR
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 99.64%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPIX
51
DELISTED
ESSA Pharma
EPIX
– –
-284,050
Closed -$8.12M
KZR
52
DELISTED
Kezar Life Sciences
KZR
– –
-69,780
Closed -$3.79M
MCRB icon
53
Seres Therapeutics
MCRB
$49.7M
– –
-12,500
Closed -$5.96M
PHVS icon
54
Pharvaris
PHVS
$2.6B
– –
-79,837
Closed -$1.49M
WGS icon
55
GeneDx Holdings
WGS
$2.66B
– –
-11,328
Closed -$5.24M
LUMO
56
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-382,000
Closed -$3.82M
CFRX
57
DELISTED
ContraFect Corporation
CFRX
– –
-724
Closed -$255K
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2021 Portfolio in Review

As of Q3 2021, Opaleye Management held 57 positions worth $535M, down 11% from $602M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management's Q3 2021 filing shows 9 new, 13 increased, 14 reduced and 9 closed positions. Its largest new stake was Semler Scientific: 225,566 shares worth $28.2M. The largest sale was ESSA Pharma, an estimated $8.12M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Opaleye Management's largest Q3 2021 buy was Semler Scientific: 225,566 shares worth $28.2M.
  • Opaleye Management added most to Crinetics Pharmaceuticals in Q3 2021, an estimated $4.22M increase.
  • Opaleye Management's biggest Q3 2021 reduction was Eton Pharmaceutcials, cutting an estimated $3.14M.
  • Opaleye Management fully exited ESSA Pharma in Q3 2021, selling an estimated $8.12M.
  • Opaleye Management's ten largest holdings make up 59% of its $535M portfolio in Q3 2021.
  • Opaleye Management opened 9 new positions and closed 9 in Q3 2021.
  • Opaleye Management's portfolio value fell 11% quarter-over-quarter to $535M.

Based on Opaleye Management's 13F filing for Q3 2021, filed 16 Nov 2021.